Connor, Clark & Lunn Investment Management Ltd. Tango Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$7.51 - $12.88 $118,552 - $203,323	15,786 Added 8.74%	196,384 $1.56 Million
Q4 2023 Feb 09, 2024	BUY	$6.52 - $12.01 $1.05 Million - $1.94 Million	161,177 Added 829.91%	180,598 $1.79 Million
Q3 2023 Nov 13, 2023	BUY	$2.93 - $11.26 $20,735 - $79,687	7,077 Added 57.33%	19,421 $218,000
Q2 2023 Aug 10, 2023	BUY	$2.67 - $4.7 $32,958 - $58,016	12,344 New	12,344 $40,000

Others Institutions Holding TNGX

# of Institutions

123

Shares Held

91.7M

Call Options Held

3.1K

Put Options Held

1.5K

Trv Gp Iv, LLC Boston, MA

16.9M
Shares

$68.8 Million
80.09% of portfolio
Eco R1 Capital, LLC San Francisco, CA

13.3M
Shares

$54.4 Million
4.45% of portfolio
Boxer Capital, LLC San Diego, CA

8.2M
Shares

$33.5 Million
3.35% of portfolio
Nextech Invest Ag

5.53M
Shares

$22.6 Million
6.95% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

5.02M
Shares

$20.5 Million
0.02% of portfolio

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $359M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account